Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.5%

2 terminated/withdrawn out of 44 trials

Success Rate

92.0%

+5.5% vs industry average

Late-Stage Pipeline

25%

11 trials in Phase 3/4

Results Transparency

13%

3 of 23 completed trials have results

Key Signals

4 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

10(40.0%)

N/A

6(24.0%)

Phase 2

6(24.0%)

Phase 1

2(8.0%)

Phase 4

1(4.0%)

25Total

Phase 3(10)

N/A(6)

Phase 2(6)

Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials

NCT02918084Phase 3Active Not Recruiting

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

Role: lead

NCT02895165Recruiting

PREgnancy and FERtility Registry

Role: lead

NCT00433420Phase 3Active Not Recruiting

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Role: lead

NCT07533084Not Yet Recruiting

Italian Validation of the Dynamic Neurocognitive Adaptation (dNA) Scale and Its Correlation With Neurocognitive Variables

Role: collaborator

NCT07507578Recruiting

A Multi-omics Approach to Disclose Progression and Underlying Biology of Head and Neck Adenoid Cystic Carcinoma

Role: collaborator

NCT07091838Completed

Lung Diffusing Capacities Normality Thresholds in Pulmonary Fibrosis and Emphysema

Role: lead

NCT04848493Completed

National Project on Vaccines, COVID-19 and Frail Patients

Role: collaborator

NCT05998837Phase 2Completed

GLUcose Transport and REnalPROtection in Chronic Kidney Disease

Role: lead

NCT06805812Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Role: collaborator

NCT03359538Phase 2Completed

Rapamycin Treatment for ALS

Role: collaborator

NCT01064635Phase 3Active Not Recruiting

Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)

Role: lead

NCT03452865Phase 3Completed

Esomeprazole to Reduce Organ Failure in Sepsis

Role: collaborator

NCT05717634Unknown

Endometrial Changes in Breast Cancer Women.

Role: collaborator

NCT04549831Recruiting

Genetic Bases of COVID-19 Clinical Variability

Role: collaborator

NCT05430503Completed

Long COVID and Post-exertional Pulmonary Diffusion

Role: lead

NCT04685447Not ApplicableCompleted

Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients

Role: collaborator

NCT04610554Completed

Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19

Role: lead

NCT01183494Phase 1Completed

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

Role: collaborator

NCT03601520Completed

Mechanisms of Pulmonary Diffusion Limitation in Systemic Sclerosis

Role: lead

NCT01769053Not ApplicableTerminated

Variable Pressure Support Trial

Role: collaborator